CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 222 enrolled
Drug / intervention
Brigatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02094573
NCT02094573Phase 2Completed
CompareCT.gov

A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Ariad Pharmaceuticals·interventional·Posted Mar 24, 2014·Updated Mar 15, 2021

In Brief

A Phase 2 clinical trial evaluating Brigatinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 222 participants.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 24, 2014
Enrollment StartJun 4, 2014
Primary CompletionFeb 29, 2016
Study CompletionFeb 27, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.3 years ago

Interventions

Brigatinibdrug

Brigatinib tablets